EnhancedBio Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 12

Employees

  • Latest Deal Type
  • M&A

EnhancedBio General Information

Description

Developer of anti-cancer therapeutics designed to introduce new drug forms for cancer treatment. The company's therapeutics focus on target-specific drugs and companion diagnostics for treating various cancers, enabling healthcare professionals to provide patients with the medicines to get improved cancer treatment.

Contact Information

Website
www.enhancedbio.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Room 708-711, 7th Floor, KM Tower
  • 95, Gasan digital 2-ro
  • Seoul, Geumcheon 08505
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
TS Trillion
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Room 708-711, 7th Floor, KM Tower
  • 95, Gasan digital 2-ro
  • Seoul, Geumcheon 08505
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EnhancedBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 27-Sep-2023 Completed Generating Revenue
4. Later Stage VC (Series C) 20-Aug-2022 Completed Clinical Trials - General
3. Early Stage VC 01-Jan-2020 Completed Clinical Trials - General
2. Early Stage VC 31-Dec-2019 $3.43M $9.9M Completed Clinical Trials - General
1. Early Stage VC (Series A) 22-Feb-2019 $6.5M $6.5M Completed Pre-Clinical Trials
To view EnhancedBio’s complete valuation and funding history, request access »

EnhancedBio Patents

  • 70

    Total Documents Applications and Grants

  • Total Patents Families

  • 26

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

EnhancedBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023212599-A2 Compounds and methods for targeted degradation of estrogen receptors Inactive 26-Apr-2022
WO-2023212599-A3 Compounds and methods for targeted degradation of estrogen receptors Inactive 26-Apr-2022
WO-2023212599-A9 Compounds and methods for targeted degradation of estrogen receptors Inactive 26-Apr-2022
WO-2023177451-A1 Compounds and methods for the targeted degradation of cyclin dependent kinases Inactive 18-Mar-2022
WO-2023023537-A1 Compounds and methods for the targeted degradation of bruton's tyrosine kinase Inactive 17-Aug-2021 C07D487/04
To view EnhancedBio’s complete patent history, request access »

EnhancedBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EnhancedBio Former Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
CKD Venture Capital Corporate Venture Capital Minority
Dongyu Technology Electronic Corporation Minority
Friend Investment Partners (Seoul) Venture Capital Minority
HB Investment Venture Capital Minority
Heungkuk Securities Corporation Minority
You’re viewing 5 of 21 investors. Get the full list »

Ready to get started?

Request a free trial

EnhancedBio FAQs

  • When was EnhancedBio founded?

    EnhancedBio was founded in 2016.

  • Where is EnhancedBio headquartered?

    EnhancedBio is headquartered in Seoul, South Korea.

  • What is the size of EnhancedBio?

    EnhancedBio has 12 total employees.

  • What industry is EnhancedBio in?

    EnhancedBio’s primary industry is Drug Discovery.

  • Is EnhancedBio a private or public company?

    EnhancedBio is a Private company.

  • What is EnhancedBio’s current revenue?

    The current revenue for EnhancedBio is .

  • How much funding has EnhancedBio raised over time?

    EnhancedBio has raised $35.6M.

  • Who are EnhancedBio’s investors?

    CKD Venture Capital, Dongyu Technology Electronic, Friend Investment Partners (Seoul), HB Investment, and Heungkuk Securities are 5 of 21 investors who have invested in EnhancedBio.

  • When was EnhancedBio acquired?

    EnhancedBio was acquired on 27-Sep-2023.

  • Who acquired EnhancedBio?

    EnhancedBio was acquired by TS Trillion.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process